COMPANY

Moonlight Bio

Keywords: cell therapy oncology solid tumors tumors Small Cell Lung Cancer Extrapulmonary Neuroendocrine Carcinoma Gastroenteropancreatic NEC Neuroendocrine Prostate Cancer ML261

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Jun 23, 2026 Trial start 1: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) source ↗

Upcoming milestones

2028-03 (ESTIMATED) · 1 · A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) · NCT07488923

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07488923	A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)	1	Recruiting	Jun 23, 2026	2028-03 (estimated)